Patient with inoperable pheochromocytoma

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F15%3A00083405" target="_blank" >RIV/00216224:14110/15:00083405 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/65269705:_____/15:00063487

Výsledek na webu

<a href="http://dx.doi.org/10.3747/co.22.2324" target="_blank" >http://dx.doi.org/10.3747/co.22.2324</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3747/co.22.2324" target="_blank" >10.3747/co.22.2324</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Patient with inoperable pheochromocytoma

Popis výsledku v původním jazyce

Malignant pheochromocytoma is a tumour with a very low incidence that occurs sporadically or in the presence of multiple endocrine neoplasia. We present the case of a woman with a sporadic occurrence of pheochromocytoma diagnosed in the phase of multipledissemination in the abdominal cavity and overexpressing adrenaline, noradrenaline, and dopamine. Local transarterial chemoembolization and systemic treatment with lanreotide resulted in a very good response, a decrease in the production of catecholamines for 12 months and a partial decrease for another 8 months, with stabilization of disease determined by imaging. Systemic treatment with tegafur resulted in disease stabilization lasting 50 months, after which the drug was discontinued because of adverse effects. Maintenance therapy with lanreotide continues, and no disease progression has been observed for 4 months.

Název v anglickém jazyce

Patient with inoperable pheochromocytoma

Popis výsledku anglicky

Malignant pheochromocytoma is a tumour with a very low incidence that occurs sporadically or in the presence of multiple endocrine neoplasia. We present the case of a woman with a sporadic occurrence of pheochromocytoma diagnosed in the phase of multipledissemination in the abdominal cavity and overexpressing adrenaline, noradrenaline, and dopamine. Local transarterial chemoembolization and systemic treatment with lanreotide resulted in a very good response, a decrease in the production of catecholamines for 12 months and a partial decrease for another 8 months, with stabilization of disease determined by imaging. Systemic treatment with tegafur resulted in disease stabilization lasting 50 months, after which the drug was discontinued because of adverse effects. Maintenance therapy with lanreotide continues, and no disease progression has been observed for 4 months.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Current Oncology

ISSN

1198-0052

e-ISSN

—

Svazek periodika

22

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

CA - Kanada

Počet stran výsledku

4

Strana od-do

"E216"-"E219"

Kód UT WoS článku

000356976100010

EID výsledku v databázi Scopus

—